IPO ChampIPO Insights
IPO Champ LogoIPO Champ Logo

IPOs

IPO Calendar
GMP Tracker
Subscription Status
Allotment Status
Stock Broker
  • Follow us on Instagram
  • Follow us on Facebook
  • Follow us on Threads
  • Follow us on YouTube
  • Follow us on Telegram
  • Follow us on WhatsApp
HomeIPORubicon Research

About Rubicon Research

Founded in 1999, Rubicon Research Limited is a pharmaceutical organization that deals with the development, manufacturing, and marketing of differentiated formulation.As of March 31, 2024, Rubicon Research Limited had an approved portfolio of 69 active Abbreviated New Drug Application (ANDA) and New Drug Application (NDA) products of the US FDA. The portfolio comprises 55 commercialized products of which the US generic pharmaceutical market size is USD 2,386.6 million and which has contributed USD 154.3 million by Rubicon Research Limited during Fiscal 2024.

Checklist Quality Analysis

Revenue Growth

Live IPOs

National Stock Exchange of India logo

National Stock Exchange of India

Mainboard
Open  Close17th Sep 2026 - 21st Sep 2026
Issue Size22561.57 Cr
Min. Qty8 Shares
Issue Price₹ 1700.00
Live IPO
Antala Industries logo

Antala Industries

SME
Open  Close29th Oct 2026 - 5th Nov 2026
Issue Size22.98 Cr
Min. Qty2000 Shares
Issue Price₹ 62.00
Live IPO
Companies NameOpen - CloseIssue SizeMin. QtyIssue PriceApply
National Stock Exchange of India logo

National Stock Exchange of India

Mainboard
17th Sep 2026 - 21st Sep 202622561.57 Cr8 Shares₹ 1700.00
Antala Industries logo

Antala Industries

SME
29th Oct 2026 - 5th Nov 202622.98 Cr2000 Shares₹ 62.00
See All Live IPOs
IPO Champ LogoIPO Champ Logo

IPO Champ helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

Tools

IPO CalendarGMP TrackerSubscription StatusAllotment Status

IPOs

All IPOsLive IPOsUpcoming IPOsClosed IPOsListed IPOs

Resources

NewseBooks

Company

HomeAbout UsPrivacy PolicyTerms of Service

About IPO Champ

IPO Champ is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
help@ipochamp.com.

Please read all offer documents and risk disclosures carefully before investing. IPO Champ does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Champ. All rights reserved.

Want to stay updated?Subscribe to our newsletter

Rubicon Research

Rubicon Research

Open Date

09 Oct 2025

Close Date

13 Oct 2025

listed

Min Investment

₹14550

Lot Size

30 Shares

Issue Size

₹1377.5 Cr

Price Range

₹461 - ₹485

Listing Date

Oct 16, 2025

IPO Doc

RHP PDF

Company Valuation

Earning Expansion

The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily.

₹130(+26.80%)GMP
26.8%Prediction Listing Gain

Grey Market Premium (GMP) Trend

Rubicon Research IPO - Issue Objectives

The company intends to use ₹310 crore towards the payment/repayment of borrowings. IPO funds will cover unidentified acquisitions and general corporate purposes.

Repayment of loans

62%

Inorganic growth and general corporate purposes

38%

1

Repayment of loans

The company intends to use ₹310 crore towards the payment/repayment of borrowings.

62.00%
2

Inorganic growth and general corporate purposes

IPO funds will cover unidentified acquisitions and general corporate purposes.

38.00%

IPO Subscription Status

Total
109.33x

Times subscribed by category (bars capped at 10x for readability). Dashed line marks 1.0x (fully subscribed).

Financials of Rubicon Research

In Cr.

Key Performance Indicator30-Jun-25 (In Cr.)31-Mar-25 (In Cr.)31-Mar-24 (In Cr.)31-Mar-23 (In Cr.)
Revenue356.951296.22872.39419.00
EBITDA79.74267.89173.0943.97
Expenses
Profit After Tax43.30134.3691.01-16.89
Assets1647.601451.431109.49749.70
Net Worth593.67540.98385.00286.38
Reserves397.50525.57369.79281.31
Borrowing495.78393.17396.41317.91

Rubicon Research - Promoter(s)

Rubicon Research

General Atlantic Singapore

Pratibha Pilgaonkar

Sudhir Dhirendra Pilgaonkar

Parag Suganchand Sancheti

Surabhi Parag Sancheti

Sumant Sudhir Pilgaonkar

Pre Issue Share Holding

N/A

Post Issue Share Holding

N/A

About Strength & Risks

Why this IPO looks interesting

Key positives investors may want to consider before applying.

01

Leading pharmaceutical company

Between FY23 and FY25, the company was the fastest-growing Indian pharmaceutical company, with a total revenue CAGR of 75.89%, which was over seven times higher than the average. The company is the only Indian pharmaceutical player fully focused on regulated markets, with 99.50% of revenue from the US in Q1FY26. Its strong presence has translated into more than 25% market share in the US (by value) for nine products in FY25 compared to only two products in FY23.

02

Data-driven product selection framework

The company leverages a robust, ROI-centric, data-driven framework for product selection that helps withstand pricing pressures in the US generics market. While the overall US generics industry witnessed a 5.2% price erosion between FY22 and FY25, the company achieved an 8.0% average per unit price growth during the same period. With a strong commercialisation rate of 86.4% of approved products as of June 2025 in the US market, the framework ensures early identification of commercially viable opportunities.

03

Strong R&D capabilities

The company’s R&D strength is backed by 170 scientists across facilities in India and Canada, focusing on formulations and complex dosage forms. It invested ₹36.74 crore in R&D in FY2025 (10.42% of revenue), maintaining a steady allocation to innovation. These FDA-inspected facilities support the development of high-value products such as nasal sprays, inhalation therapies, and speciality drugs, with 72 active ANDAs and 9 NDAs as of June 2025.

What investors should watch closely

Risk factors and possible pressure points around the offer.

01

High dependence on the US market

The company derives nearly all its revenue from the United States, with 99.50% as of June 2025 and 98.58% in FY25. Any policy change, tariff imposition, pricing pressure, or regulatory reform in the US healthcare sector could materially impact its business.

02

Regulatory & product recall risk

The company’s products are subject to stringent regulations in multiple jurisdictions, including the USFDA, CDSCO India, MHRA UK, TGA Australia, and Health Canada. Its top five products take an average of 41–45 months to reach the market, with R&D spends of ₹5.71 crore in FY2025 and ₹8.49 crore in Q1FY26. Any delay in approvals, non-compliance with cGMP, or adverse inspection outcomes could result in penalties, recalls, or product seizures, materially impacting growth and profitability.

Registrar Contact Details

Axis Capital LtdIIFL Capital Services LtdJM Financial LtdSBI Capital Markets Ltd

MedOne House, B-75, Road No. 33, Wagle Estate, Thane West-400604, Maharashtra, India Thane, Maharashtra, 400604

02261414000
rubicon.ipo@linkintime.co.in
https://www.rubicon.co.in/

Rubicon Research IPO - FAQs

Rubicon Research IPO is a Mainboard IPO. The issue is priced at ₹461-485 per equity share. The minimum order quantity is 30 Shares. The IPO opens on 9 Oct, and closes on 13 Oct. Axis Capital LtdIIFL Capital Services LtdJM Financial LtdSBI Capital Markets Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.

IPO Timeline

  • Pre Apply2025-10-08
  • Bidding Starts2025-10-09
  • Bidding Ends2025-10-13
  • Allotment Finalisation2025-10-14
  • Release of Funds2025-10-15
  • Demat Transfer2025-10-15
  • Listing2025-10-16
04

Robust sales and distribution capacity in the US

Through its wholly-owned subsidiary AdvaGen Pharma, the company directly markets over 350 SKUs to 96 customers, including all three major US wholesalers that control 90% of distribution. Validus further extends branded sales capabilities, with distribution across 44 states and strong CNS prescriber relationships.

05

Cost-effective manufacturing

According to F&S, the company’s manufacturing facilities are based in India, where the cost of manufacturing is 30-40% lower than in the US. This enables the company to compete in developed markets while minimising cost. Further, it also utilised third-party manufacturing during periods when its facilities were highly utilised or were not equipped for specific types of manufacturing, allowing the company to meet demand and maintain supply.

03

Customer concentration risk

The company depends heavily on a few customers, with the top five contributing 71.22% of revenues in FY25 and 77.04% as of June 2025. One customer (TruPharma) alone accounted for 17.16% of revenues as of June 2025. Loss of a key customer or adverse contract terms could materially reduce revenues and weaken bargaining power.

04

Foreign exchange risk

With 98.49% of FY25 revenues from exports in the US and 99.50% as of June 2025, the company is exposed to currency volatility. Unhedged exposures stood at USD -$835.35 crore as of June 2025. Net forex gains have already declined sharply from ₹15.67 crore in FY24 to ₹8.31 crore in FY25. Further, in addition, certain of its borrowings are denominated in USD, and any such depreciation of the Indian rupee against the USD may impact the financial condition.